by Truveta staff | Apr 8, 2024 | Research
Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2019 to December 2023. During the early months of the COVID-19 pandemic, the rate of syphilis incidence (e.g., new infection) increased significantly, reaching a...
by Truveta staff | Jan 26, 2024 | Research
Truveta Research explored the rates of pediatric RSV immunizations and pediatric RSV-associated hospitalizations for children under the age of two. Of the 1,872,292 children under age two who were eligible to receive an RSV immunization, 3.7% of the eligible...
by Truveta staff | Jan 25, 2024 | News
Today Truveta is excited to announce that the company is a finalist at the 2024 South by Southwest (SXSW) Innovation Awards recognizing Truveta Language Model (TLM) in the Artificial Intelligence (AI) category. This prestigious accolade not only acknowledges...
by Truveta staff | Jan 17, 2024 | Technology
The pace of new therapy adoption has been limited by the ability to produce data that the medical community trusts. Clinical researchers have historically had difficulty accessing and cleaning healthcare data, wrestling with hard-to-use tools, and developing and...
by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
